Research and Markets: Acute Leukaemia's Persistent Unmet Needs Confer Significant Commercial Opportunity; Commercial Opportunities within the Acute Leukaemia Market are Rife.

DUBLIN, Ireland -- Research and Markets http://www.researchandmarkets.com/reports/c35636 has announced the addition of Acute Leukaemia's - Persistent Unmet Needs Confer Significant Commercial Opportunity to their offering

While existing treatment strategies for adult acute leukaemia may yield satisfactory remission- induction rates, a major clinical concern is the high rate of disease relapse despite attempts to optimize post-remission consolidation therapy. This is acutely problematic among elderly patients who are frequently unable to tolerate the rigors of more intensive treatment approaches.

Report Scope:

-Overview of acute leukaemia's including epidemiology, etiology, disease classification and prognostic variables.

-Current treatment controversies and novel therapies in the developmental pipeline.

-Analysis of trial data, marketing factors and commercial potential for key technologies in clinical development.

Stakeholder opinions and interview transcripts based on qualitative interviews with key opinion leaders from the US and Europe.

Report Highlights:

-For the innovators of novel and efficacious pharmacotherapy, commercial opportunities within the acute leukaemia market are rife. Developers can exploit the high unmet needs that currently prevail in the acute leukaemia market by using accelerated approval pathways to expedite market access and drive commercialization

-Future drug development approaches will respond to the increased identification of gene mutations and their ensuing proteonomic manifestations. This approach is more likely to address the heterogeneity of acute leukaemia and will contribute to the increasing trend of risk-stratified treatment approaches.

-Reflecting a greater understanding of disease biology, the enthusiastic pursuit of Flt-3 inhibition in the development of novel acute myeloid leukaemia treatment has resulted in already crowded pipeline, with four products challenging for first-to-market status: Cephalons CEP-701, Novartis PKC-412, Millenniums MLN518 and Pfizers SU11248.

Reasons to order your copy:

-Identify the areas of unmet need and clinical controversy in acute leukaemia treatment.

-Understand how advancements in acute leukaemia prognostication and risk--stratification may shift future treatment paradigms

-Assess opportunities and risks for innovative treatments targeting the acute leukaemias.

Companies mentioned include:

Bioenvision

Clolar

Genta

Gleevec

Pfizers

Millennium

Novartis

Cephalon 

Source: Datamonitor

For more information visit http://www.researchandmarkets.com/reports/c35636